Recently, four COVID-19 vaccine products have been approved for emergency use. The companies involved are Wantai Biotech and Sinopharm Celltech.-Uwait.mRNAVaccines are the mainstream technology route for COVID-19 vaccines approved for marketing abroad. In terms of research and development progress, companies such as Watson Biotech, CanSino Biologics, and Shijiazhuang Pharmaceutical Group are ahead in product development. The reporter noticed that Fosun Pharma has beenBioNTechintroducedmRNAThe COVID-19 vaccine 'Fubaitai' has been approved for marketing in Hong Kong, Macao and Taiwan regions.
How do you view the prospects of domestic COVID-19 vaccines? Which technical route holds more promise for development? There are no domestic products yetmRNAThe launch of COVID-19 vaccines, and how it is viewed as businesses compete for technological layoutmRNAVaccine? What is the outlook for domestic COVID-19 vaccines going global? Frost & SullivanFrost & SullivanLi Qian, Senior Consulting Director for Healthcare in Greater China at Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan'), was interviewed "Cainiao News Agency" An interview was held to discuss the domestic COVID-19 vaccine industry.
Cailian Finance & Economics News Agency
Q
Cainiao News Agency Reporter: Currently, there are four technical routes for COVID-19 vaccines in China. There are more companies whose products have been approved for market release or are under development. Some believe that the space for COVID-19 vaccines is limited, with the main focus on booster shots and the fourth dose in the future. What is your view on the prospects of domestic COVID-19 vaccines?
The protection after COVID-19 vaccination declines over time, and booster shots are needed. In addition, continuous mutation of the COVID-19 virus strains can lead to immune evasion, requiring additional immunization against variant strains. In the future, it is also possible that COVID-19 vaccines become similar to influenza vaccines, becoming a requirement for annual vaccination. Therefore, booster shots, the fourth dose, and routine vaccination are the main potential areas for COVID-19 vaccines in the future.
Recently, the vaccination work against COVID-19 in China has accelerated once again, which also confirms the aforementioned market growth points:11month17On the same day, Shen Hongbing, deputy director of the National Disease Control and Prevention Administration, stated at a press conference that relevant departments are formulating plans to accelerate the vaccination against the novel coronavirus.11month29On the same day, the 'Work Plan for Strengthening COVID-19 Vaccination among the Elderly' was issued. The notice proposes to accelerate the increase in the vaccination rate of the elderly with the COVID-19 vaccine and shorten the time interval between booster shots for the elderly from six months to three months.
Cainiao News Agency Reporter: Which technology route do you see has a brighter development prospect?
Currently, most existing COVID-19 vaccines only provide immunity against a single strain. Therefore, multivalent vaccines that can prevent multiple variants of the novel coronavirus deserve attention. In addition, considering the gradual implementation of booster shots and the fourth dose, multiple injections can be burdensome for populations. The introduction of new administration methods for COVID-19 vaccines is also quite promising. For example, inhalable COVID-19 vaccines can be administered by mouth, with an inhalation dose about one-fifth that of the intramuscular dose, thereby improving vaccination compliance.
Q
Cailian News Agency Reporter: There are no domestic products in our countrymRNAWith the launch of COVID-19 vaccines, how do you view companies competing to make technological arrangements?mRNAVaccine?
mRNAAs a brand-new technical approach, vaccines have the advantages of safety, high protection rates, rapid production, economy, and large-scale manufacturing. They have been approved for marketing.mRNAVaccines have also been creating business legends globally.
Domestic enterprises are mostly located in2019Established around the New Year, it has a short development history and may not have as much technical reserve in the short term as it did more than a decade ago.ModernaandBioNTech, but layoutmRNAVaccines are actually also an entry pointmRNAAn important step in the emerging field of therapies, with time, I believe domestic companiesmRNAGreat progress has been made in the field of therapies.
Q
Cainiao News Agency Reporter: What is the outlook for domestic COVID-19 vaccines going global?
The global coverage rate of COVID-19 vaccines is not uniform, and vaccination in low-income countries and regions may be the main battlefield for domestic COVID-19 vaccines to go global. According toOur World in DataStatistical data, as of2022year12month8On the same day, although the vaccination rate of COVID-19 vaccines in developed countries has tended to saturate, only24.9%People in low-income countries have received at least one dose of the COVID-19 vaccine. In addition, considering the demand for booster shots, fourth doses, and routine vaccination, the prospects for domestic COVID-19 vaccines going global are very promising.
*This interview was published in "Cainiao Communications".APPReporter Wang Junxian, original title: "Thousand sails" competition! There is still a suspense regarding the domestic COVID-19 vaccine to be resolved.|Industry Observation >> (Click 'Read the Original Article' at the end of the text to read the full report).
